• SINAT–V-ATPase Control of Plant Autophagy

  2026-08-16

  A 2026 Arabidopsis study identifies VAB1 as a SINAT-regulated determinant of autophagic vesicle degradation, linking ubiquitin-dependent protein turnover to V-ATPase activity and vacuolar acidification. The work shifts attention from autophagosome formation to the less understood terminal degradation step and provides a framework for testing intracellular pH as a functional readout of plant autophagy.

• POx Lipids as PEG Alternatives in mRNA LNPs

  2026-08-15

  Holick and colleagues evaluate poly(2-ethyl-2-oxazoline)-based lipids as substitutes for PEG-lipids in mRNA lipid nanoparticles, linking polymer chain length with particle size, immune response, transfection, and uptake mechanisms. Their combination of formulation analysis and super-resolution microscopy identifies a PEtOx-LNP that outperforms the commercial PEG-lipid comparator under the study conditions, while also clarifying why uptake and functional expression should be measured separately.

• Lipid Peroxidation and Sunitinib Resistance

  2026-08-14

  Ferroptosis research is moving from descriptive oxidative-stress measurements toward mechanistic, translational evidence. This article connects the OTUD3–SLC7A11 pathway in clear cell renal cell carcinoma with practical malondialdehyde quantification using the Lipid Peroxidation (MDA) Assay Kit.

• Neomycin sulfate for RNA/DNA Structure Studies

  2026-08-14

  Neomycin sulfate is an aminoglycoside antibiotic that can serve as a mechanistic probe for RNA catalysis, HIV-1 Tat–TAR recognition, DNA triplexes, and ryanodine receptor channels. This guide translates those capabilities into practical assay workflows while separating product-driven structural studies from the microbiome and immune findings of an allergic-rhinitis rat study.

• Leupeptin: Translational Control of Protease Biology

  2026-08-13

  Leupeptin hemisulfate salt offers reversible, competitive control of serine and cysteine proteases. This thought-leadership guide connects mechanistic protease inhibition with autophagy, viral replication, protein degradation, and rigorous TET2-centered translational workflows.

• TMEM16F, Ferroptosis, and Tumor Immune Rejection

  2026-08-13

  Yang and colleagues identify TMEM16F-mediated plasma-membrane lipid scrambling as an execution-phase suppressor of ferroptosis. Their findings connect membrane biophysics to tumor immunity, showing that disabling lipid scrambling can increase ferroptotic lysis, release danger signals, slow tumor growth, and enhance PD-1 blockade.

• CB-5083: Practical p97 Inhibitor Workflows

  2026-08-12

  CB-5083 enables mechanism-focused studies of p97-dependent protein quality control, from cellular ubiquitin accumulation to apoptosis and xenograft response. This guide pairs practical dosing and readout strategies with ER lipid-homeostasis insights that help distinguish proteostasis effects from secondary organelle phenotypes.

• Gramine Suppresses TNBC via CUL3–MTDH Ferroptosis

  2026-08-12

  The reference study identifies gramine as an inhibitor of triple-negative breast cancer that acts through a CUL3–MTDH regulatory axis to promote ferroptosis. Its combination of target-engagement assays, genetic perturbation, ferroptosis rescue, and xenograft validation provides a useful mechanistic framework for studying ferroptosis-driven anticancer activity.

• GW 4869 for Exosome Mechanism Studies

  2026-08-11

  GW 4869 links neutral sphingomyelinase inhibition with practical exosome-release experiments, enabling researchers to test whether vesicle transfer drives disease phenotypes. This workflow uses donor–recipient controls, cargo validation, and viability checks to distinguish reduced extracellular vesicles from nonspecific toxicity.

• Aztreonam: From MIC to Mechanism-Aware Assays

  2026-08-11

  Aztreonam is a monocyclic β-lactam antibiotic with selective activity against Gram-negative aerobes. This article develops a mechanism-aware assay framework linking susceptibility testing with resistance interpretation, bone marrow progenitor cell inhibition, and hepatic cytochrome P450 research.

• AR Heterogeneity and Enzalutamide Response in CRPC

  2026-08-10

  Li and colleagues showed that heterogeneous androgen receptor expression defines biologically distinct castration-resistant prostate cancer populations with different responses to enzalutamide. By combining patient tissues, engineered LNCaP clones, xenografts, transcriptomics, and combination treatments, the study identified AR status and BCL-2 dependence as practical considerations for response modeling.

• Self-Adaptive Nanocarriers for Pancreatic Cancer

  2026-08-09

  The ACS Nano study developed a pH/reactive oxygen species dual-sensitive nanocarrier, DATCPT, that adapts its charge and generates peroxynitrite to overcome circulation, extracellular matrix, and tumor-penetration barriers. Its orthotopic pancreatic cancer experiments support a coordinated delivery strategy in which tumor-associated acidity and oxidative stress activate both drug release and microenvironment remodeling.

• Indomethacin as a Mechanistic Bridge in Translational Resear

  2026-08-08

  Indomethacin is more than a conventional nonsteroidal anti-inflammatory drug: its COX inhibition, PPAR activity, and membrane effects make it a useful perturbation tool for inflammation research, lipid metabolism study, and membrane signaling modulation. This article positions Indomethacin alongside the FXR–KLF11 findings reported in contrast-induced acute kidney injury while clearly separating established evidence from translational hypotheses.

• Epalrestat Activates KEAP1/Nrf2 in Parkinson’s Models

  2026-08-07

  Jia et al. identify Epalrestat as a potential neuroprotective agent in Parkinson’s disease models and provide evidence that it directly binds KEAP1, promotes KEAP1 degradation, and activates Nrf2 signaling. The findings connect an established aldose reductase inhibitor with oxidative stress and mitochondrial dysfunction pathways, while remaining preclinical and requiring validation beyond toxin-based models.

• ATRX Loss Increases Glioma Sensitivity to Selective PDGFR In

  2026-08-07

  The reference study demonstrates that ATRX-deficient high-grade glioma cells exhibit heightened sensitivity to receptor tyrosine kinase (RTK) and PDGFR inhibitors. These findings highlight the potential of ATRX status as a biomarker for targeted therapy and inform the design of future clinical trials in aggressive gliomas.

8527 records 3/569 page Previous Next 12345 下5页 Last page